Novartis announced that its highly selective Bruton tyrosine kinase inhibitor Rhapsido® has been approved by the US FDA to treat symptomatic skin blemishes in adults who are unable to fully control symptoms after H1 antihistamines. This is also a new indication that the drug expanded after chronic spontaneous urticaria.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.